Actively Recruiting

Age: 18Years - 38Years
FEMALE
Healthy Volunteers
NCT06732843

Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of Cumulus Cells During Antral Follicle Growth and Impact Blastocyst Status?

Led by ART Fertility Clinics LLC · Updated on 2025-07-25

10

Participants Needed

1

Research Sites

105 weeks

Total Duration

On this page

Sponsors

A

ART Fertility Clinics LLC

Lead Sponsor

M

Merck Sharp & Dohme LLC

Collaborating Sponsor

AI-Summary

What this Trial Is About

Gonal-F® (follitropin alfa) is a recombinant FSH without LH activity, while Menopur® contains both LH and hCG. The MEGASET trial compared Menopur® and Gonal-F® in GnRH antagonist cycles with SET, showing similar efficacy. A subsequent study (MEGASET-HR) in high responders found ongoing pregnancy rates of 35.5% for Menopur® and 30.7% for Gonal-F®, with a lower early pregnancy loss for Menopur® (14.5% vs 25.5%). Telomere length (TL) in oocyte cumulus cells (CC) correlates with oocyte quality and embryo outcomes. This study aims to assess whether stimulation type (hMG vs. Gonal-F) affects TL in CC and subsequent blastocyst development. A randomized, open-label, cross-over study in normo-responders will analyze telomere length, embryo quality, and hormonal markers.

CONDITIONS

Official Title

Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of Cumulus Cells During Antral Follicle Growth and Impact Blastocyst Status?

Who Can Participate

Age: 18Years - 38Years
FEMALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Maternal age 18 - 38 years
  • Patients requested PGT-A
  • BMI 18- 30kg/m2
  • Expected normoresponders
  • Fresh autologous ejaculate (65 mill/ml)
  • Sperm abstinence: 2-3 days
  • Normal female/male karyotype
  • Regular menstrual cycle length: 25-32 days
  • AFC of 5-10 in each ovary at the beginning of the stimulation
  • Trigger: dual trigger: 2.500 IU urinary hCG + 0.3 mg Decapeptyl
  • A wash-out period between 1 to 3 months; an inter-cycle variation of 10% in AFC, measured by the same physician, is accepted
  • Couple agrees to perform two stimulations before continuing with embryo transfer
Not Eligible

You will not qualify if you...

  • Uterine abnormalities as diagnosed by ultrasound
  • Any hormonal or oral contraceptive pretreatment within 3 months before treatment
  • Endometriosis classified as stage 3 or higher according to American Fertility Society
  • History of 2 or more miscarriages
  • Poor ovarian response based on Bologna criteria

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

ART Fertility Clinics

Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates

Actively Recruiting

Loading map...

Research Team

D

Daniela Nogueira

CONTACT

J

Jonalyn DV Edades

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here